The resurgence of tuberculosis is ascribed to co-infection with immunodeficiency virus, and the emergence of Mycobacterium tuberculosis drug-resistant strains. New molecules should be useful to fight both drug-susceptible as well as drug-resistant strains. The two principal research routes to find out new antibacterial molecules and novel bacterial targets are from drug to target and from target to drug. Until now the first one appears to be the most easily attainable, leading to the discovery of new molecules which are currently in clinical trials and the last published benzothiazinones and dinitrobenzamides.
Fighting against resistant strains: the case of benzothiazinones and dinitrobenzamides
BURONI, SILVIA;RICCARDI, GIOVANNA;PASCA, MARIA ROSALIA
2012-01-01
Abstract
The resurgence of tuberculosis is ascribed to co-infection with immunodeficiency virus, and the emergence of Mycobacterium tuberculosis drug-resistant strains. New molecules should be useful to fight both drug-susceptible as well as drug-resistant strains. The two principal research routes to find out new antibacterial molecules and novel bacterial targets are from drug to target and from target to drug. Until now the first one appears to be the most easily attainable, leading to the discovery of new molecules which are currently in clinical trials and the last published benzothiazinones and dinitrobenzamides.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
